Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vitamin d3 + dapagliflozin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Vitamin d3 + dapagliflozin is a combination therapy being investigated for the treatment of hypertension and obstructive sleep apnea (OSA). This combination consists of dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, and vitamin D3 (colecalciferol), a secosteroid that acts as a vitamin D receptor agonist. The therapy is being studied by University Malaysia Sarawak (UNIMAS) to evaluate its synergistic effects on cardio-metabolic markers, heart rate variability, and the renin-angiotensin-aldosterone system (RAAS) in obese patients with CPAP-naive OSA. Dapagliflozin promotes urinary glucose excretion and diuresis, while vitamin D3 supplementation is intended to address deficiencies common in OSA patients and potentially modulate blood pressure and metabolic health.
- Brand names
- ForxigaFarxiga
- Other names
- Vitamin D3 plus DapagliflozinVitamin D and SGLT-2 inhibitor combination
02
Targets
VDR (Vitamin D receptor)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on vitamin d3 + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vitamin d3 + dapagliflozin.